Local News
Eyewitness Sports
Medical Coverage
Call 12 For Action
Target 12 Investigators
More Details
What's On WPRI
What's On Fox
This Morning Weekend
Experts Online
Online Store
Chopper 12
Station Info

 May 12, 2005
Pfizer Plan to Sell Bundled Cholesterol Drugs Stirs Controversy
Email to a Friend Printer Friendly Version  

Pfizer Inc. is already making headlines with an experimental cholesterol drug that promises to boost a person's HDL (so-called "good" cholesterol), unlike the revolutionary statin drugs that work by ridding the body of LDL ("bad" cholesterol).

Experts have no qualms with preliminary studies that show the drug can substantially raise a person's HDL. What's drawing their ire is Pfizer's plan to sell the drug only in combination with its best-selling statin Lipitor, The New York Times reports.

The new drug, called torcetrapib, isn't expected to hit store shelves until at least 2007, the newspaper said. Some studies have shown that it may raise blood pressure, a serious problem for any heart patient.

Nonetheless, critics say Pfizer is making a mistake by offering the important new treatment only as a bundled drug. They say some patients may benefit more if the drug were used with other statins, or even as a stand-alone pill. The plan to bundle the two drugs, some say, is nothing more than a clever attempt to protect Lipitor from competing medications.

Pfizer, according to the newspaper, says torcetrapib and Lipitor work in complementary ways, and that it's natural for patients to take both. While the statin drug works to cut LDL levels that can cause a buildup of fatty plaques in the arteries, torcetrapib may actually stop the buildup of plaque itself, the Times reported.


Copyright � 2005 ScoutNews, LLC. All rights reserved.

Health News | Health Encyclopedia | Quizzes and Tools | Women's Health | Men's Health | Children's Health | Seniors' Health | Diet, Fitness and Self Image | Sex and Relationships

Nutrition News  more» 
Yemen Reports Growing Polio Outbreak
Fen-Phen Replacement Leads to Weight Loss, Maker Says
Knee Problems Linked to Obesity
FDA Warns Pfizer About Zoloft Magazine Ad
19 School Kids Get HIV Drugs After Needle Stick
Senate to Consider Tightened Abortion Restrictions
Report Urges Changes to Nutrition Program
Ephedra Ban Lifted by U.S. District Judge
Bextra Pulled From Market
Pfizer Withdraws Bextra From Market
Health Encyclopedia: Nutrition
Vitamin E
Send questions and comments about this website to the .
All content © Copyright 2003-2005 WorldNow, WPRI, WNAC and Associated Press. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.